ArticleThe Journal of clinical endocrinology and metabolism2023
Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine.
Article in The Journal of clinical endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study
Investigating Glycated Albumin Use for Short-Term and Additional/Alternate Monitoring of Blood Glucose Control
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Glycated albumin: An old yet new biomarker in people with diabetes and the potential for novel applications.Journal of diabetes investigation · 2026Review
- Associations of GA and GMI/GA Ratio With All-Cause Mortality in Well-Controlled Type 2 Diabetes Defined by Continuous Glucose Monitoring.Diabetes/metabolism research and reviews · 2026Article
- Glycemic assessment when hemoglobin A1c is unreliable: a clinical-laboratory framework for kidney disease, anemia, and hemoglobinopathies.Frontiers in endocrinology · 2026Review
- Scoping Review-Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions.Journal of diabetes science and technology · 2025Review
- Association of time in tight range and 1,5-anhydroglucitol in type 2 diabetes.Diabetes, obesity & metabolism · 2025Article
- Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring.Diabetes care · 2025Article
- Glycated Albumin and Continuous Glucose Monitoring Metrics in Dogs with Diabetes Mellitus: A Pilot Study.Animals : an open access journal from MDPI · 2025Article
- The Relationship Between Glycated Albumin and Time in Tight Range in Type 2 Diabetes.Journal of diabetes · 2025Article
- Efficacy of Self-Review of Lifestyle Behaviors with Once-Weekly Glycated Albumin Measurement in People with Type 2 Diabetes: A Randomized Pilot Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine.The Journal of clinical endocrinology and metabolism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
contextIntermediate-term glycemic control metrics may represent a viable alternative to continuous glucose monitoring (CGM) in patients without access to CGM.
objectiveThis work aimed to compare the relationship between CGM parameters and glycated albumin (GA), glycated hemoglobin A1c (HbA1c), and fructosamine for 24 weeks.
methodsWe conducted exploratory comparative analyses of CGM subgroup data from a previously published 24-week prospective study of assay performance in 8 US clinics. Participants included 34 individuals with type 1 (n = 18) and type 2 diabetes (n = 16) undergoing changes to improve glycemic control (n = 22; group 1) or with stable diabetes therapy (n = 12; group 2). Main outcome measures included Pearson correlations between CGM and glycemic indices and receiver operating characteristic (ROC) analysis of glycemic index values predictive of time in range (TIR) greater than 70%.
resultsAt weeks 4 and 8, GA correlations with TIR were higher than HbA1c correlations in group 1. In group 2, GA correlations with TIR were statistically significant, whereas HbA1c correlations were not. In both groups over the first 12 weeks, GA correlations with TIR were higher than fructosamine-TIR correlations. In the ROC analysis, GA predicted a TIR greater than 70% during weeks 2 to 24 (area under the curve >0.80); HbA1c was predictive during weeks 12 to 24. Cutoff values for TIR greater than 70% were 17.5% (sensitivity and specificity, 0.88) for GA and 7.3% (0.86) for HbA1c.
conclusionGA is the most accurate predictor of TIR over 8 weeks compared with other glycemic indices, which may assist in clinical evaluation of changes in treatment where CGM is not possible and it is too early to use HbA1c (NCT02489773).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.